While traditional medical tourism destinations like Thailand and South Korea focus on services such as cosmetic surgery and IVF, China is positioning itself as a leader in advanced medical treatments, particularly in oncology. According to Victor Cao, operations director of Joyful Medical in Shanghai, patients are increasingly attracted to China due to the availability of cutting-edge treatments at competitive prices. A prime example is CAR-T therapy, a groundbreaking cancer treatment that is either unavailable or prohibitively expensive in many countries. In the U.S., a single CAR-T infusion can cost between $300,000 and $475,000, while in China, it ranges from $150,000 to $180,000, with plans to offer a therapy priced below $44,000. China’s medical tourism sector, though still developing, is expected to grow significantly, increasing from $1.3 billion in 2025 to $3.4 billion by 2035, as it aims to shift its global image and meet rising international demand for advanced healthcare services.
Why It Matters
China’s push into the medical tourism market reflects its broader economic strategy to transition from a manufacturing hub to a provider of high-value services. The global medical tourism market is projected to grow from $34 billion to $126 billion by 2035, indicating substantial potential for countries like China. The establishment of the Lecheng International Medical Tourism Pilot Zone in Hainan highlights China’s efforts to attract foreign patients by offering access to advanced therapies not available domestically. As the country continues to improve its healthcare technologies and service quality, its appeal as a medical tourism destination is likely to increase, addressing the needs of patients seeking advanced treatments abroad.
Want More Context? 🔎
